Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 71, Issue 3, 2009, Pages 409-419

  Maeda, H ^a   Bharate, G Y ^a   Daruwalla, J ^b  

^a SOJO UNIVERSITY   (Japan)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Advantages of nanomedicine; EPR effect; Factors of EPR effect; Nanomedicine; Nanoparticles; Polymer drug conjugates; Polymeric micelles; Solubilization; Tumor targeted drug delivery

Indexed keywords

ANGIOTENSIN II; ASPARAGINASE MACROGOL; DOXORUBICIN; GALLIUM; GELATIN; IODINATED POPPYSEED OIL; MACROGOL; METHOTREXATE; MONOCLONAL ANTIBODY; NK 911; PEGINTERFERON ALPHA2A; PIRARUBICIN; POLYVINYL ALCOHOL; PYRAN COPOLYMER; STYRENE MALEIC ANHYDRIDE COPOLYMER; SUPEROXIDE DISMUTASE MACROGOL; TRANSFERRIN; TRASTUZUMAB; UNCLASSIFIED DRUG; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

BLOOD VESSEL PERMEABILITY; BREAST CANCER; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; ENHANCED PERMEABILITY AND RETENTION EFFECT; HUMAN; HYPERTENSION; IMMUNOPOTENTIATION; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LYMPHATIC LEUKEMIA; NONHUMAN; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; POLYMERS; TISSUE DISTRIBUTION;

EID: 60749108001     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.11.010     Document Type: Review

References (122)

1. H. Maeda, A. Kabanov, K. Kataoka, T. Okano (Eds.), Polymer Drugs in the Clinical Stage Advantages and Prospects, vol. 519, Plenum Publishers, New York, 2003, pp. 1-69.
2. Langer R. Drug delivery and targeting. Nature 392 (1998) 5-10
3. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003) 347-360
4. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6 (2006) 688-701
5. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor tropic accumulation of proteins and antitumor agent SMANCS. Cancer Res. 46 (1986) 6387-6392
6. Maeda H., and Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6 (1989) 193-210
7. Maeda H., Sawa T., and Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 74 (2001) 47-61
8. Greish K., Iyer A.K., Fan J., and Maeda H. Enhanced permeability and retention (EPR) effect and tumor-selective delivery of anticancer drugs. In: Torchillin V.P. (Ed). Delivery of Protein and Peptide Drugs to Cancer (2006), Imperial College Press, London 37-52
9. Greish K., Fang J., Inutsuka T., Nagamitsu A., and Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumor targeting. Clin. Pharmacokinet. 42 (2003) 1089-1095
10. Tobias S., Sian J., Laura D., Wood D., and Parsons W. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
11. Wood L.D., Williams Parsons D., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., Silliman N., Szabo S., Dezso Z., Ustyanksky V., Nikolskaya T., Nikolsky Y., Karchin R., Wilson P.A., Kaminker J.S., Zhang Z., Croshaw R., Willis J., Dawson D., Shipitsin M., Willson V., Sukumar S., Polyak K., Park B.H., Pethiyagoda C.L., Krishna Pant P.V., Ballinger D.G., Sparks A.B., Hartigan J., Smith D.R., Suh E., Papadopoulos N., Buckhaults P., Markowitz S.D., Parmigiani G., Kinzler K.W., Velculescu V.E., and Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
12. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.E., DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal PA., and Stratton M.R. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
13. A. Jack, H. Simonian, Roche to Switch to Primary Care Force, Financial Times (European Ed.), July 2, 2008.
14. Rawlins M. Clinical leadership at NICE, editorial page. Lancet 372 (2008) 601
15. Seymour L., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., and Duncan R. Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31A (1995) 766-770
16. Reddy L.H. Drug delivery to tumors: recent strategies. J. Pharm. Pharmacol. 57 (2005) 1231-1242
17. Maeda H. SAMNCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 6 (1991) 181-202
18. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
19. Konno T., Maeda H., Iwai K., Tashiro S., Maki S., Morinaga T., Mochinaga M., Hiraoka T., and Yokoyama I. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur. J. Cancer Clin. Oncol. 19 (1983) 1053-1065
20. Konno T., Maeda H., Iwai K., Maki S., Tashiro S., Uchida M., and Miyauchi Y. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54 (1984) 2367-2374
21. Iwai K., Maeda H., and Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 44 (1984) 2115-2121
22. Maki S., Konno T., and Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 56 (1985) 751-757
23. Harrington K.J., Mohammadtaghi S., Uster P.S., Glass D., Peters A.M., Vile R.G., and Stewart J.S.W. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 7 (2001) 243-254
24. Maeda H., Takeshita J., and Kanamaru R. A lipophilic derivative of neocarsinostatin. A polymer conjugation of antitumor protein antibiotic. Int. J. Pept. Protein Res. 14 (1979) 81-87
25. Greish K., Nagamitsu A., Fang J., and Maeda H. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjug. Chem. 16 (2005) 230-236
26. Greish K., Sawa T., Fang J., Akaike T., and Maeda H. SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumors. J. Control. Release 97 (2004) 219-230
27. Iyer A.K., Greish K., Seki T., Okazaki S., Fang J., Takeshita K., and Maeda H. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J. Drug Target. 15 (2007) 496-506
28. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., Shirao K., Okusaka T., Ueno H., Ikeda M., and Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 91 (2004) 1775-1781
29. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24 (2007) 1-16
30. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
31. Gabzon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19 (2001) 424-436
32. Iwai K., Maeda H., Konno T., Matsumura Y., Yamashita R., Yamasaki K., Hirayama S., and Miyauchi Y. Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res. 7 (1987) 321-327
33. Kimura N., Taniguchi S., Aoki K., and Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res. 40 (1980) 2060-2068
34. Gao X., Cui Y., Levenson R.M., Chung L.W., and Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22 (2004) 969-976
35. Stroh M., Zimmer J.P., Duda D.G., Levchenko T.S., Cohen K.S., Brown E.B., Scadden D.T., Torchilin V.P., Bawendi M.G., Fukumura D., and Jain R.K. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med. 11 (2005) 678-682
36. Leaf C.F. Why we are losing the war on cancer and how to win it. Fortune 149 (2004) 76-97
37. Miklos G.L. The human cancer genome project-one more misstep in the war on cancer. Nat. Biotechnol. 23 (2005) 535-537
38. Meares C.F. What's new, the chemistry of targeting, editorial comment. Bioconjug. Chem. 19 (2008) 1-4
39. Hassett M.J., Omalley A.J., Pakes J.R., Newhouse J.P., and Earle C.C. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of woman with breast cancer. J. Natl. Cancer Inst. 98 (2006) 1108-1117
40. Erban J.K., and Lau J. On the toxicity of chemotherapy for breast cancer-the need of vigilance. J. Natl. Cancer Inst. 98 (2006) 1096-1097
41. Tannock I.F., Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N., Turesson I., Rosenthal M., and Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351 (2004) 1502-1512
42. Kantoff P.W., Halabi S., and Conaway M. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer. J. Clin. Oncol. 17 (1999) 2506-2513
43. Miyamoto Y., Oda T., and Maeda H. Comparison of the cytotoxic effects of the high and low molecular weight anticancer agents on multi drug resistance Chinese hamster ovary cells in vitro. Cancer Res. 50 (1990) 1571-1575
44. Miyamoto Y., and Maeda H. Enhancement by verapamil of neocarzinostatin action on multidrug-resistant. Chinese hamster ovary cells: possible release of non-protein chromophore in cells. Jpn. J. Cancer Res. 82 (1991) 351-356
45. Molla A., Matsumura Y., Yamamoto T., Okamura R., and Maeda H. Pathogenetic capacity of proteases from Serratia marcesens and Pseudomonas aeruginosa and their suppression by chicken egg white ovomacroglobulin. Infect. Immun. 55 (1987) 2509-2517
46. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., and Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89 (1998) 307-314
47. Seymour L.W., Ulbrich K., Steyger P.S., Brereton M., Subr V., Strohalm J., and Duncan R. Tumor tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70 (1994) 636-641
48. Duncan R., and Sat Y.N. Tumor targeting by enhanced permeability and retention (EPR) effect. Ann. Oncol. 9 Suppl. 2 (1998) 39
49. Duncan R. Polymer conjugates for tumor targeting and intra-cytoplasmic delivery. The EPR effect as a common gateway?. Pharm. Sci. Technol. Today 2 (1999) 441-449
50. Matsumoto K., Yamamoto T., Kamata R., and Maeda H. Pathogenesis of serratial infection: activation of the Hageman facto-perkallikerin cascade by serratial protease. J. Biochem. 96 (1984) 739-749
51. Kamata R., Yamamoto T., Matsumoto K., and Maeda H. A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs. Infect. Immun. 48 (1985) 747-753
52. Molla A., Yamaoto T., Akaike T., Miyashim S., and Maeda H. Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J. Biol. Chem. 264 (1989) 10589-10594
53. Maruo K., Akaike T., Inada Y., Ohkubo I., Ono T., and Maeda H. Effect of microbial and mite proteases on low and high molecular weight kininogens. J. Biol. Chem. 268 (1993) 17711-17715
54. Maeda H., Fang J., Inuzuka T., and Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3 (2003) 319-328
55. Maeda H., Matsumura Y., and Kato H. Purification and identification of [hydroxypropyl] bradykinin in ascetic fluid from a patient with gastric cancer. J. Biol. Chem. 263 (1988) 16051-16054
56. Matsumura Y., Kimura M., Yamamoto T., and Maeda H. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 79 (1988) 1327-1334
57. Matsumura Y., Konno T., and Maeda H. Kinin generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res. 82 (1991) 732-741
58. Wu J., Akaike T., and Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58 (1998) 159-165
59. Wu J., Akaike T., Hayashida K., Miyamoto Y., Nakagawa T., Miyakawa K., Esterl W.M., and Maeda H. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int. J. Cancer 98 (2002) 29-35
60. Skinner S.A., Tutton P.J., and O'Brien P.E. Microvascular architecture of experimental colon tumors in the rat. Cancer Res. 50 (1990) 2411-2417
61. Malcontenti-Wilson C., Muralidharan V., Skinner S., Christophi C., Sherris D., and O'Brien P.E. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin. Cancer Res. 7 (2001) 1052-1060
62. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., and McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156 (2000) 1363-1380
63. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756
64. Maeda H., Noguchi Y., Sato K., and Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85 (1994) 331-334
65. Doi K., Akaike T., Horie H., Noguchi Y., Fujii S., Beppu T., Ogawa M., and Maeda H. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 77 Suppl. 8 (1996) 1598-1604
66. Wu J., Akaike T., Hayashida K., Okamoto T., Okuyama A., and Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn. J. Cancer Res. 92 (2001) 439-451
67. Okamoto T., Akaike T., Sawa T., Miyamoto Y., Ravdavliet A., and Maeda H. Activation of matrix metalloproteinase by peroxynitrite induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 276 (2001) 29596-29602
68. Tanaka S., Akaike T., Wu J., Fang J., Sawa T., Ogawa M., Beppu T., and Maeda H. Modulation of tumor selective vascular blood flow and extravasation by the stable prostaglandin I2 analogue beraprost sodium. J. Drug Target. 11 (2003) 45-52
69. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
70. Hori K., Suzuki M., and Tande S. Fluctuation in tumor blood flow and effect of angiotensin induced hypertension. Jpn. J. Cancer Res. 82 (1991) 1309-1316
71. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237 (1999) 97-132
72. Papetropoulos A., Garcia-Cardena G., Madri J.A., and Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100 (1997) 3131-3139
73. Maeda H., Takeshita J., and Yamashita A. Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin. Eur. J. Cancer 16 (1979) 712-731
74. Takeshita J., Maeda H., and Kanamaru R. In vitro mode of action, pharmacokinetics and organ specificity of poly (maleic acid-styrene)-conjugated neocarsinostatin, SMANCS. Gann 73 (1982) 278-284
75. Maeda H., Takeshita J., Kanamaru R., Sato H., Khatoh J., and Sato H. Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent and water-soluble polymer conjugated protein. Gann 70 (1979) 601-606
76. Maeda H., Matsumoto T., Konno T., Iwai K., and Ueda M. Tailor-making of protein drugs by polymer conjugation for tumor targeting, a brief review on SMANCS. J. Protein Chem. 3 (1984) 181-193
77. Eggermont A.M., Suciu S., Santinami M., Testori A., Kruit W.J., Marsden J., Punt C.J.A., Sales R., Gore M., Mackie R., Kusic S., Dummer R., Hauschild A., Musat E., Spatz A., and Keilholz U. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet 372 (2008) 117-126
78. Suzuki M., Hori K., Abe Z., Saito S., and Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 67 (1981) 663-669
79. Li J., Miyamoto Y., Kojima Y., and Maeda H. Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 67 (1993) 975-980
80. Nagamitsu A., Inuzuka T., Greish K., and Maeda H. SMANCS dynamic therapy for various advanced solid tumors and promising clinical effects: enhanced drug delivery by hydrodynamic modulation with vascular mediators, particularly angiotensin II, during arterial infusion. Drug Deliv. Syst. 22 (2007) 510-521
81. Matsumura Y. Preclinical and clinical studies of anticancer drug incorporated polymeric micelles. J. Drug Target. 15 (2007) 507-517
82. Maeda H., Kimura M., Sasaki I., Hirose Y., and Konno T. Toxicity of bilirubin and detoxification by PEG-bilirubin oxidase conjugate. In: Milton Harris J. (Ed). Poly(Ethylene Glycol) Chemistry: Biomedical Applications (1992), Plenum Press, New York 153-169
83. Heathcote E.J., Mitchell M.L., Graganm W., Cooksley E., Dusheiko G.M., Lee S.S., Balart L., Reindollar R., Reddy R.K., Wright T.L., Lin A., Hoffman J., and De Pamphilis J. Peginterferon alfa-2a in patient with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343 (2000) 1673-1680
84. Suzuki F., Munakata T., and Maeda H. Interferon induction by SMANCS: a polymer-conjugated derivative of neocarzinostatin. Anticancer Res. 8 (1988) 97-103
85. Oda T., Morinaga T., and Maeda H. Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Proc. Soc. Boil. Med. 181 (1986) 9-17
86. Suzuki F., and Kobayashi M. Immunomodulating antitumor mechanisms of SMANCS. In: Maeda H., Edo K., and Ishida N. (Eds). Neocarzinostatin the Past Present and Future of Anticancer Drug (1997), Springer, Tokyo, Berlin, New York 167-186
87. Masuda E., and Maeda H. Host-mediated antitumor activity induced by neocarzinostatin and its polymer conjugated derivative in tumor bearing mice. In: Maeda H., Edo K., and Ishida N. (Eds) (1997), Springer, Tokyo, Berlin, New York 187-204
88. Oda T., Akike T., Hamamoto T., Suzuki F., Hirano T., and Maeda H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 244 (1989) 974-976
89. Akaike T., Okamoto S., Sawa T., Yoshitake J., Tamura F., Ichimori K., Miyazaki K., Sasamoto K., and Maeda H. 8-Nitroguanosine formation in viral pneumonia and its implication for pathogenesis. Proc. Natl. Acad. Sci. USA 100 (2003) 685-690
90. Maeda H., and Akaike T. Oxygen free radicals as pathogenic molecules in viral diseases. Proc. Soc. Exp. Biol. Med. 198 (1991) 721-727
91. Akaike T., and Maeda H. Nitric oxide and viral infection. Immunology 10 (2000) 300-308
92. 2: improved stability of SOD in vitro and in vivo. J. Bioact. Compat. Polym. 11 (1996) 169-190
93. Kojima Y., Haruta A., Imai T., Otagiri M., and Maeda H. Conjugation of Cu, Zn-Superoxide dismutase with succinylated gelatin: pharmacological activity and cell-lubricating function. Bioconjug. Chem. 4 (1993) 490-498
94. 2 plus Cu, Zn-superoxide dismutase reflects the activity of free copper release from the oxidatively damaged enzyme. J. Biol. Chem. 267 (1992) 25371-25377
95. Kimura M., Matsumura Y., Konno T., Miyauchi Y., and Maeda H. Enzymatic removal of bilirubin toxicity by bilirubin oxidase in vitro and excreation of degradation products in vivo(43199). Proc. Soc. Exp. Biol. Med. 195 (1990) 64-69
96. Maeda H., Nishi K., and Mori I. Facilitating effects of alpha-1 acid glycoprotein on the passage of erythrocytes through the membrane-filter. Life Sci. 27 (1980) 157-161
97. Maeda H., Morinaga T., Mori I., and Nishi K. Further characterization of the effects of alpha-1 acid glycoprotein on the passage of human erythrocytes through micropores. Cell Struct. Funct. 9 (1984) 279-290
98. Matsumura Y., Yokoyama M., Kataoka K., Okano T., Sakurai Y., Kawaguchi T., and Kakaizoe T. Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles. Jpn. J. Cancer Res. 90 (1999) 122-128
99. Sumitomo M., Koizumi F., Asano T., Horiguchi A., Ito K., Asano T., Kakizoe T., Hayakawa M., and Matsumura Y. Novel SN-38 incorporated polymeric micelle NK012 strongly suppresses renal cancer progression. Cancer Res. 68 (2008) 1631-1635
100. J. Singer, B. Baker, P.D. Vries, A. Kumar, S. Shaffer, E. Vawter, M. Bolton, P. Garzone, Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTEXTM], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology and preliminary clinical data, polymeric drugs in the clinical stage, advances and prospects, in: H. Maeda, A. Kabanov, K. Kataoka, T. Okano (Eds.), vol. 519, Plenum Publishers, New York, 2003, pp. 81-100.
101. Oka K., Miyamoto Y., Matsumura Y., Tanaka S., Oda T., Suzuki F., and Maeda H. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug SMANCS in an oily formulation. Pharm. Res. 7 (1990) 852-855
102. Hirayama S., Sato F., Oda T., and Maeda H. Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase, comparative study with neocarzinostatin. Jpn. J. Antibiot. 39 (1986) 815-822
103. Oda T., and Maeda H. Binding to and internalization by cultured cells of neocarsinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer. Cancer Res. 47 (1987) 3206-3211
104. Oda T., Sato F., and Maeda H. Facilitated internalization of neocarsinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. J. Natl. Cancer Inst. 79 (1987) 1205-1211
105. Vincent J., and Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 24 (2006) 39-47
106. Wanger E., Curiel D., and Cotton M. Delivery of drugs, proteins and genes into cells using transferrin as ligand for receptor-mediated endocytosis. Adv. Drug Deliv. Rev. 14 (1994) 113-136
107. Miyajima Y., Nakamura H., Kuwata Y., Lee J.D., Masunaga S., Ono K., and Maruyama K. Transferrin-loaded nido-carborane liposomes: tumor targeting boron delivery system for neutron capture therapy. Bioconjug. Chem. 17 (2006) 1314-1320
108. Leamon C.P., Reddy J.A., Vlahov I.R., Kleindl P.J., Vetze M., and Westrick E. Synthesis and biological evaluation of EC 140: a novel folate-targeted vinca alkaloid conjugate. Bioconjug. Chem. 17 (2006) 1226-1232
109. Maeda H., Molla A., Sakamoto K., Murakami A., and Matsumura Y. Cytotoxicity of bacterial proteases in various tumor cells mediated through α2-macroglobulin receptor. Cancer Res. 49 (1989) 660-664
110. Murakami A., Sakamoto K., Kojima Y., Sasaki Y., and Maeda H. Antitumor effect of bacterial proteases on various human xenografts in nude mice. Reg. Cancer 4 (1992) 200-206
111. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2 (2002) 750-765
112. Pellegrin P., Fernandez A., Lamb N.J.C., and Bennes R. Macromolecular uptake is a spontaneous event during mitosis in cultured fibroblast: implications for vector-dependent plasmid transfection. Mol. Biol. Cell 13 (2002) 570-578
113. Stastny M., Strohalm J., Plocova D., Ulbrich K., and Rihova B. A possibility to overcome pegycoprotein (PPG)mediated multidrug resistance by antibody targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur. J. Cancer 35 (1999) 459-466
114. Minko T., Kopeckova P., Pozharov V., and Kopecek J. HPMA copolymer bound adriamycin overcomes MDRI gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 54 (1998) 223-233
115. Minko T., Barakova E.V., Li S., Pakunulu R.I., Alakhov V.Y., and Kabanov A.V. Pluronic block copolymer alter apoptotic signal transduction of doxorubicin in drug resistant cancer cells. J. Control. Release 105 (2005) 269-278
116. Mayerhofer M., Gleixner K.V., Hormann G., Sonneck K., Aichberger K.J., Ott R.G., Greish K., Nakamura H., Derdak S., Samorapoomichit P., Pickl W.F., Sexl V., Esterbauer H., Stilaber C., Maeda H., and Valent P. Targeting of heat shock protein 32 (Hsp32)/heme oxygenease-1(HO-1) in leukemic cell in chronic myeloid leukemia: a novel approach to overcome resistgance against imatinib. Blood 111 (2008) 2200-2210
117. Graham M.L. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 55 (2003) 1293-1302
118. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 (2003) 214-221
119. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., Okuwa M., Matsumoto S., Miyata Y., Ohkura H., Chin K., Baba S., Yamao T., kannami A., Takamatsu Y., Ito K., and Takahashi K. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15 (2004) 517-525
120. Imai T. Species difference of drug metabolism: difficulty of prediction of drug disposition in human from animal data. J. Jpn. Soc. Drug Deliv. Syst. 22 (2007) 48-53
121. Davis M.E., Chen Z., and Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7 (2008) 771-782
122. J. Daruwalla, K. Greish, C.M. Wilson, V. Muralidharan, H. Maeda, C. Christophi, SMA-pirarubicin micelles improve survival and inhibit the growth of colorectal metastases by inducing apoptosis, Tumor Biol., in press.